AdvanCell
About AdvanCell
AdvanCell is a Therapeutics startup based in Brisbane, Australia that has raised $427M in venture capital across 3 funding rounds since 2019. The company reached Series D stage in August 2022 with a $12M round led by Morningside. AdvanCell's investor base includes 7 institutional funds, with Ally Bridge Group leading the most recent equity round.
AdvanCell is a clinical-stage radiopharmaceutical company developing Lead-212 (Pb-212) based Targeted Alpha Therapies (TAT) for cancer. Its lead candidate, ADVC001, is a Pb-212 PSMA-targeted alpha therapy for metastatic castration-resistant prostate cancer advancing toward Phase 3 registrational studies. The company operates a vertically integrated model spanning proprietary isotope supply, automated manufacturing, and clinical development across Australia and the United States.
AdvanCell Funding Rounds Timeline
3 rounds · $427M raised · since 2019
| Round | Date | Amount | Valuation | Lead investor | Co-investors |
|---|---|---|---|---|---|
| Series B | August 2022 | $12M | — | Morningside | — |
| Series C | February 2025 | $112M | — | SV Health Investors | Sanofi Ventures, Abingworth, SymBiosis, Morningside, Eli Lilly and Company, Tenmile, Brandon Capital |
| Series D | July 2026 | $315M | — | Ally Bridge Group | Alpha Wave Ventures, Bain Capital Life Sciences, Fidelity Management & Research Company, T. Rowe Price Associates, Eventide Asset Management, SV Health Investors, Sanofi Ventures, Abingworth, Morningside, Eli Lilly and Company, Brandon Capital |
Investors in AdvanCell
7 institutional investors across 3 rounds
Lead investors
Co-investors
Recent news about AdvanCell
Questions about AdvanCell
How much has AdvanCell raised?
AdvanCell has raised $427M across 3 funding rounds since 2019.
Who are the investors of AdvanCell?
AdvanCell's investors include Ally Bridge Group, Alpha Wave Ventures, SV Health Investors, Bain Capital Life Sciences, Sanofi Ventures, Morningside Ventures, Brandon Capital.
When was AdvanCell's last funding round?
AdvanCell's most recent round was a $12M Series B in August 2022, led by Morningside.
Where is AdvanCell headquartered?
AdvanCell is headquartered in Brisbane, Australia, and was founded in 2019.